Celgene and Pharmacyclics requested the U.S. Patent and Trademark Office (USPTO) to reject Kyle Bass' petition to invalidate their patents citing the reason that the hedge fund manager is abusing its review process.

Kyle Bass through the Coalition for Affordable Drugs is challenging some of the patents of pharmaceutical companies to "lower drug prices for Medicare and everyone."

In February, the hedge fund manager's Coalition for Affordable Drugs started filing patent petitions through a process called inter partes review to eliminate major drug patents.The coalition filed 16 petitions including five against Celgene, one of the largest biotechnology companies worldwide.

Celgene stressed in its filing with the Patent Trial and Appeal Board that "it will be inundated with similar petitions, and no public company that relies on patents to protect its innovations will be safe from threats or unnecessary petitions from for-profit organizations" if it allows Kyle Bass to continue misusing the review process as part of an investment strategy.